Articles 11 to 20 of 48
Wharton - The company faces a dearth of new drugs to replace top sellers due to lost patent protection in the next few years, and has canceled work on a highly anticipated depression drug that failed in late-stage trials. Wharton faculty and outside analysts
Source: knowledge.wharton.upenn.edu
Click here for more information about information on depression 2 information on depression 2
